When a Kenyan is diagnosed with cancer, the odds of survival look nothing like they would in a wealthier country, and the difference has little to do with how often the disease strikes. New country-level data released alongside the World Health Organization’s Global Status Report on Cancer 2026 shows that Kenya’s cancer survival odds lag well behind the global average, and further still behind high-income countries, a gap driven almost entirely by what happens, or fails to happen, between diagnosis and treatment. 

A Kenya-focused report by the Global Cancer Observatory and Cancer Today found that of every 100 Kenyans diagnosed with cancer, around 64 will die of it, compared with roughly 35 in high-income countries and 47 worldwide. In 2024, an estimated 35,867 Kenyans were diagnosed with cancer, roughly 13,914 men and 21,953 women, and of those diagnoses, 22,888 people died. At any given moment, around 76,165 people in the country are living with cancer, and a Kenyan’s lifetime risk of a cancer diagnosis by age 75 stands at 12.3 per cent. 

Kenya’s rate of new diagnoses, 111 cases per 100,000 people, is not unusually high by global standards; it ranks 163rd in the world. What sets the country apart is not how often cancer appears, but how often it kills once it does. The death rate, 74.6 per 100,000, tells the real story. 

Women account for 61 per cent of Kenya’s cancer cases, driven largely by breast and cervical cancer, which together make up 46 per cent of all cancers diagnosed in women. Breast cancer alone accounted for 5,822 new cases in 2024, followed by cervical cancer with 4,294 and prostate cancer with 3,601. 

Oesophageal cancer is Kenya’s most lethal, concentrated along the Rift Valley corridor 

Not all cancers carry the same odds, and the differences in Kenya are stark enough to matter for anyone trying to understand their own risk. Oesophageal cancer is the country’s most lethal, concentrated along the Rift Valley corridor. It kills 93 of every 100 people diagnosed with it, a fatality rate that outpaces almost every other cancer tracked. Cervical cancer, Kenya’s second most common cancer overall, claims 61 lives for every 100 diagnoses. 

Breast cancer is comparatively the most survivable of Kenya’s common cancers. Even so, it still takes one life for every two diagnoses, a death rate far higher than a woman would face with the same disease in a wealthy country. Catching breast cancer early, before it spreads beyond the breast and nearby lymph nodes, happens in 91 per cent of cases in high-income countries. In low- and middle-income countries with usable data, that figure drops to just 28 per cent, less than a third as often. 

In wealthier countries, 74 per cent of the population has been screened for cervical cancer within the last five years. In poorer countries, that figure is 26 per cent. And when it comes to actually getting treated, hospitals in wealthy countries stock essential cancer medicines 81 per cent of the time, against just 31 per cent in poorer settings. 

Each of these gaps, screening, early diagnosis and access to medicine, makes the others worse. Miss the screening, and a cancer is caught late. Catch it late, and the medicine needed to treat it is often the kind poorer hospitals are least likely to have in stock. That chain of missed opportunities is a large part of why a Kenyan diagnosis carries such different odds from one made in a wealthier country. 

Researchers on gynaecological cancers found that Eastern Africa has highest incidence of such cancers globally 

Eastern Africa records some of the lowest cancer incidence rates in the world, at 99.8 new cases per 100,000 men, roughly a third of the rate seen in Australia, New Zealand or Northern Europe. Researchers believe the low numbers largely reflect gaps in registration and detection rather than genuinely fewer people getting cancer. In other words, cases are not being counted because they are not being diagnosed in the first place. 

Research on gynaecological cancers found that Eastern Africa actually has the highest incidence of these cancers in the world, above 50 per 100,000, and the highest mortality rate of any global region too, closely tied to overlapping rates of HIV and HPV infection in the region. Similarly, a separate analysis found Eastern Africa responsible for 30 per cent of all colorectal cancer deaths recorded across Africa in 2022, second only to North Africa. 

Across sub-Saharan Africa as a whole, the American Cancer Society estimates around 820,000 new cancer cases and 550,000 deaths in 2022. Breast, cervical and prostate cancer together make up two-fifths of all cases in the region, and cervical cancer is the single leading cause of cancer death among women in sub-Saharan Africa. Cancers linked to infections, chiefly HPV and hepatitis B, account for roughly 80 per cent of preventable cancer cases across the region. Vaccination and screening programmes exist on paper across East Africa, but several gaps point to low uptake of tests and follow-up care. 

At continental scale, Africa accounted for just 5.9 per cent of new cancer cases worldwide in 2022, yet 7.8 per cent of global cancer deaths. That mismatch, a smaller share of cases but a larger share of deaths, is perhaps the clearest single measure of a continent where cancer tends to be diagnosed late and treated with fewer resources than almost anywhere else. 

The WHO’s 2026 report shows that only 39 per cent of countries worldwide include even a basic package of cancer care in their universal health coverage, leaving much of the world without guaranteed access to treatment. Where treatment does exist, it can bankrupt families trying to pay for it: the report documents treatment abandonment rates as high as 90 per cent in some settings, driven by out-of-pocket costs. 

Health worker shortages in poorer countries mean cancer care staff report high rates of burnout 

Hospital availability of essential cancer medicines ranges from just 9 to 54 per cent in low-income countries, compared with 68 to 94 per cent in high-income ones. Health worker shortages in poorer countries run two to five times worse than in wealthier ones, and cancer care staff in these settings report high rates of burnout. 

By 2021, the number of countries with a national cancer control plan had risen from half in 2010 to 82 per cent. But the WHO report notes that only 28 per cent of countries have actually built comprehensive cancer care into their funded health benefits. 

The WHO’s report, titled The Future We Choose Together, estimates that 20.6 million people were diagnosed with cancer globally in 2024, a figure projected to reach 35 million a year by 2050. One in five people alive today will develop cancer at some point in their life, and once family members are counted, the report estimates that around 92 per cent of everyone alive today will be touched by cancer in some way. 

Cancer was the leading cause of premature death in 41 countries in 2021, the second leading cause in 37 more, and the third in a further 47. Only 12 countries worldwide are currently on track to meet the global target of cutting premature cancer deaths by a third by 2030, while 48 countries are seeing rates rise instead. 

Global tobacco use has fallen by around 27 per cent since 2010, and 155 countries now have at least one best-practice tobacco control measure in place, up from just 44 in 2007. HPV vaccination coverage among girls has climbed from 17 per cent in 2019 to 31 per cent globally, and 85 per cent of countries have folded HPV vaccination into their national immunisation programmes, even in places where uptake still lags behind. 

Sources: WHO/IARC, Global Status Report on Cancer 2026, GLOBOCAN 2024/2022 via IARC Global Cancer Observatory, Global Cancer Statistics 2024,CA: A Cancer Journal for Clinicians; ACS Cancer Atlas; JCO Global Oncology. Kenya figures: GLOBOCAN 2024.  

Data visualisation by Stanley Njihia 

Text by Yvonne Kawira